Canada Pension Plan Investment Board Invests $241.22 Million in Bristol Myers Squibb Company $BMY

Key Points

• Canada Pension Plan Investment Board acquired 4.19 million Bristol Myers Squibb shares worth approximately $241.2 million, representing a 0.20% stake. Institutional investors collectively own 76.41% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $66.06, though some firms recently downgraded the stock to “Hold” or “Neutral.”
• Bristol Myers Squibb exceeded quarterly earnings and revenue expectations, reporting $2.04 in EPS and $12.97 billion in revenue, while paying a quarterly dividend of $0.63 per share for a 3.7% annualized yield.

Canada Pension Plan Investment Board acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 4,186,444 shares of the biopharmaceutical company's stock, valued at approximately $241,223,000. Canada Pension Plan Investment Board owned 0.20% of Bristol Myers Squibb at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $34,406,000. Lazard Asset Management LLC lifted its holdings in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC grew its position in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock valued at $5,322,000 after purchasing an additional 21,196 shares during the period. Callan Family Office LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $3,575,000. Finally, BlackRock Inc. raised its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. Jefferies Financial Group lowered Bristol Myers Squibb from a "buy" rating to a "hold" rating in a report on Wednesday, August 5th. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Finally, TD Cowen began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "buy" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Trading Up 0.9%

NYSE:BMY opened at $67.86 on Wednesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The firm has a 50-day moving average price of $61.01 and a two-hundred day moving average price of $59.54. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market cap of $138.62 billion, a price-to-earnings ratio of 14.95, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source